NCT07340424

A Prospective, Open-label, Single-arm, Exploratory Clinical Trial to Evaluate the Safety and Tolerability of 225Ac-TR2205 Injection in Patients With Triple-negative Breast Cancer.

• Status: Recruiting
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 15 (estimated)
• Sponsor: Xiaorong Sun · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is a prospective, single-center, single-arm, open-label research. It evaluates the safety and tolerability of 225Ac-TR2205 in patients with triple-negative breast cancer (TNBC), and assesses its radiation dosimetry and initial efficacy.

Conditions

• Advanced Metastatic Triple-negative Breast Cancer (mTNBC)

Interventions

Type	Name	Description
DRUG	225Ac-TR2205 Injection	Patients will receive 225Ac-TR2205 injection administration at an interval of 8 weeks between each dose.

Timeline

• Start date: 2025-05-22
• Primary completion: 2027-04-01
• Completion: 2029-05-01
• First posted: 2026-01-14
• Last updated: 2026-01-14

Locations

1 site across 1 country: China